Role of Neutrophil CD64 and Monocyte HLA-DR Markers in the Dignosis of Neonatal Sepsis

Launched by SOHAG UNIVERSITY · Aug 7, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how certain markers in the blood can help diagnose neonatal sepsis, a serious condition in newborns caused by infections. The researchers are specifically looking at two markers: CD64 found on neutrophils (a type of white blood cell) and HLA-DR found on monocytes (another type of immune cell). By understanding how these markers behave in newborns suspected of having sepsis, the goal is to improve diagnosis and treatment for this life-threatening condition.

To participate in the trial, newborns aged from 1 day to 28 days who show signs of possible sepsis may be eligible. This includes babies whose mothers had risk factors during delivery, such as a fever or prolonged labor. However, babies who have already started antibiotics before coming to the hospital or those with specific birth complications or certain health conditions will not be included. Families who participate can expect their baby's blood to be tested for these markers, which may help in understanding and managing sepsis better in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Neonates of both sexes included in this study with any suspected case of neonatal sepsis with maternal risk factors for sepsis , e.g., prolonged labor , premature rupture of membrane (PROM) , maternal intrapartum fever and chorioamnionitis , and neonates with sepsis-related clinical signs: temperature instability, apnea , need for supplemental oxygen ,bradycardia , tachycardia , hypotension , hypoperfusion , feeding intolerance and abdominal distension ,
• Exclusion Criteria:
• • are the adminstration of antibiotic therapy prior to admission , birth asphyxia , laboratory finding suggestive of inborn error of metabolism , and congenital anomalies including congenital heart diseases .